NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 509.33 Million USD | -5.3% |
| 2022 | 537.84 Million USD | 0.53% |
| 2021 | 535.03 Million USD | 8.23% |
| 2020 | 494.36 Million USD | 40.72% |
| 2019 | 351.31 Million USD | 41.62% |
| 2018 | 248.06 Million USD | 40.13% |
| 2017 | 177.02 Million USD | 113.57% |
| 2016 | 82.88 Million USD | 150.52% |
| 2015 | 33.08 Million USD | 113.6% |
| 2014 | 15.49 Million USD | 49.53% |
| 2013 | 10.35 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 138.5 Million USD | 3.53% |
| 2024 Q2 | 150.35 Million USD | 8.56% |
| 2024 Q3 | 155.09 Million USD | 3.15% |
| 2023 FY | 509.33 Million USD | -5.3% |
| 2023 Q2 | 126.05 Million USD | 3.17% |
| 2023 Q3 | 127.32 Million USD | 1.01% |
| 2023 Q4 | 133.78 Million USD | 5.08% |
| 2023 Q1 | 122.18 Million USD | -4.86% |
| 2022 Q1 | 137.54 Million USD | 3.25% |
| 2022 Q3 | 130.99 Million USD | -7.01% |
| 2022 Q4 | 128.42 Million USD | -1.96% |
| 2022 FY | 537.84 Million USD | 0.53% |
| 2022 Q2 | 140.86 Million USD | 2.41% |
| 2021 Q4 | 133.21 Million USD | -0.29% |
| 2021 FY | 535.03 Million USD | 8.23% |
| 2021 Q1 | 134.69 Million USD | -6.43% |
| 2021 Q2 | 133.51 Million USD | -0.87% |
| 2021 Q3 | 133.6 Million USD | 0.07% |
| 2020 FY | 494.36 Million USD | 40.72% |
| 2020 Q4 | 143.95 Million USD | 8.51% |
| 2020 Q3 | 132.66 Million USD | 14.44% |
| 2020 Q2 | 115.92 Million USD | 13.84% |
| 2020 Q1 | 101.82 Million USD | 2.61% |
| 2019 Q4 | 99.23 Million USD | 7.79% |
| 2019 Q1 | 73.3 Million USD | 5.22% |
| 2019 Q2 | 86.71 Million USD | 18.28% |
| 2019 FY | 351.31 Million USD | 41.62% |
| 2019 Q3 | 92.06 Million USD | 6.17% |
| 2018 Q3 | 64.75 Million USD | 5.27% |
| 2018 Q1 | 52.12 Million USD | -2.86% |
| 2018 FY | 248.06 Million USD | 40.13% |
| 2018 Q4 | 69.67 Million USD | 7.59% |
| 2018 Q2 | 61.51 Million USD | 18.01% |
| 2017 Q1 | 34.88 Million USD | 15.34% |
| 2017 Q2 | 38.37 Million USD | 10.02% |
| 2017 Q4 | 53.66 Million USD | 7.09% |
| 2017 Q3 | 50.1 Million USD | 30.57% |
| 2017 FY | 177.02 Million USD | 113.57% |
| 2016 Q1 | 13.05 Million USD | 5.41% |
| 2016 Q3 | 21.67 Million USD | 20.96% |
| 2016 Q4 | 30.24 Million USD | 39.53% |
| 2016 Q2 | 17.91 Million USD | 37.28% |
| 2016 FY | 82.88 Million USD | 150.52% |
| 2015 Q1 | 5.2 Million USD | 37.02% |
| 2015 FY | 33.08 Million USD | 113.6% |
| 2015 Q3 | 8.95 Million USD | 36.83% |
| 2015 Q2 | 6.54 Million USD | 25.63% |
| 2015 Q4 | 12.38 Million USD | 38.31% |
| 2014 FY | 15.49 Million USD | 49.53% |
| 2014 Q1 | 3.19 Million USD | 0.0% |
| 2014 Q2 | 4.12 Million USD | 29.09% |
| 2014 Q3 | 4.37 Million USD | 6.11% |
| 2014 Q4 | 3.8 Million USD | -13.1% |
| 2013 FY | 10.35 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | -427.085% |
| AngioDynamics, Inc. | 303.91 Million USD | -67.593% |
| AtriCure, Inc. | 399.24 Million USD | -27.575% |
| Avinger, Inc. | 7.65 Million USD | -6556.273% |
| Azenta, Inc. | 665.07 Million USD | 23.416% |
| BioLife Solutions, Inc. | 143.27 Million USD | -255.507% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 85.825% |
| Daxor Corporation | 1.28 Million USD | -39676.028% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | -2686.465% |
| Femasys Inc. | 1.07 Million USD | -47414.203% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | -353.753% |
| Hologic, Inc. | 4.03 Billion USD | 87.362% |
| ICU Medical, Inc. | 2.25 Billion USD | 77.454% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 92.85% |
| KORU Medical Systems, Inc. | 28.51 Million USD | -1686.044% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | -163.246% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -44094.992% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -44094.992% |
| Masimo Corporation | 2.04 Billion USD | 75.131% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | -424.556% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 59.492% |
| Nephros, Inc. | 14.23 Million USD | -3477.314% |
| NEXGEL, Inc. | 4.08 Million USD | -12356.297% |
| NEXGEL, Inc. | 4.08 Million USD | -12356.297% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | -17397.011% |
| OraSure Technologies, Inc. | 405.47 Million USD | -25.616% |
| Pro-Dex, Inc. | 53.84 Million USD | -845.951% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | -28512.999% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | -2566.084% |
| QuidelOrtho Corporation | 2.99 Billion USD | 83.01% |
| Repligen Corporation | 638.76 Million USD | 20.262% |
| Sanara MedTech Inc. | 64.98 Million USD | -683.719% |
| STAAR Surgical Company | 322.41 Million USD | -57.976% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | -914.133% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 87.154% |
| Jin Medical International Ltd. | 19.82 Million USD | -2469.629% |